Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OPKO HEALTH, INC.OPK · Entity 4891 | Director · SVP OPKO; Exec Chairman BRLI | May 10, 2021 | June 01, 2021 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | SVP & Group Exec. Diag. Sol. | March 08, 2018 | March 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OPKO HEALTH, INC.
Report date May 10, 2021 · Filed June 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
After 2021-05-10 transaction · row 1
1 source rowRow 1 · 2021-05-10 · Purchase · Acquired 50,000 · Balance 125,000 |
QUEST DIAGNOSTICS INC
Report date March 08, 2018 · Filed March 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,757 |
Ending reported balance
After 2018-03-08 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2018-03-08 · Exercise / conversion · Acquired 38,928 · Balance 115,426 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018. Row 2 · 2018-03-08 · Sale · Disposed 18,037 · Balance 97,389 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018. F2: This transaction was executed in multiple trades at prices ranging from $103.65 to $104.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2018-03-08 · Sale · Disposed 1,427 · Balance 95,962 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018. F3: This transaction was executed in multiple trades at prices ranging from $104.66 to $104.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2018-03-08 · Sale · Disposed 18,164 · Balance 77,798 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018. F4: This transaction was executed in multiple trades at prices ranging from $103.68 to $104.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2018-03-08 · Sale · Disposed 1,300 · Balance 76,498 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018. F5: This transaction was executed in multiple trades at prices ranging from $104.70 to $104.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2018-03-08 · Sale · Disposed 34,168 · Balance 42,330 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018. F6: This transaction was executed in multiple trades at prices ranging from $103.65 to $104.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2018-03-08 · Sale · Disposed 2,800 · Balance 39,530 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018. F7: This transaction was executed in multiple trades at prices ranging from $104.70 to $104.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2018-03-08 · Sale · Disposed 7,773 · Balance 31,757 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018. |
| Non-Qualifed Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.51 · Expires 2026-02-25 | Direct | 19,464 |
Reported balance
After 2018-03-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-03-08 · Exercise / conversion · Disposed 38,928 · Balance 19,464 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018. F8: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018.
F2: This transaction was executed in multiple trades at prices ranging from $103.65 to $104.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $104.66 to $104.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $103.68 to $104.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $104.70 to $104.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $103.65 to $104.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $104.70 to $104.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Talkspace, Inc.
Report date August 17, 2026 · Filed August 17, 2026
Section 16 reporting ended · disclosed 2026-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-08-17 · Disposition to issuer · Disposed 1,581,499 · Balance 0 F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time"). F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding share of Issuer common stock, par value $0.0001 per share ("Common Stock") (other than shares of Common Stock canceled pursuant to the Merger Agreement) was converted into the right to receive $5.25 in cash (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-08-17 · Disposition to issuer · Disposed 1,260,308 · Balance 0 F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer restricted stock unit (an "RSU") outstanding immediately prior to the Effective Time that remains unvested at the Effective Time was assumed by Parent and converted into a Parent restricted stock unit award relating to a number of shares of Class B Common Stock, par value $0.01 per share, of Parent ("Parent Class B Shares") equal to the product of (i) the number of shares of Common Stock underlying such RSU, multiplied by (ii) a fraction (a) the numerator of which was the closing price of Common Stock on Nasdaq on the last day on which Common Stock was traded on Nasdaq that is immediately prior to the date of the Effective Time and (b) the denominator of which was the closing price of a Parent Class B Share on the New York Stock Exchange on the last day on which Common Stock was traded on Nasdaq that is immediately prior to the date of the Effective Time (the "Exchange Ratio"). |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.86 | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-17 · Disposition to issuer · Disposed 662,500 · Balance 0 F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option that was or became vested in accordance with its terms at the Effective Time (each, a "Vested Stock Option") was canceled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of Common Stock subject to such Vested Stock Option immediately prior to the Effective Time and (ii) the excess, if any, of (a) the Merger Consideration over (b) the per share exercise price of such Vested Stock Option. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-17 · Disposition to issuer · Disposed 200,211 · Balance 0 F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option that was or became vested in accordance with its terms at the Effective Time (each, a "Vested Stock Option") was canceled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of Common Stock subject to such Vested Stock Option immediately prior to the Effective Time and (ii) the excess, if any, of (a) the Merger Consideration over (b) the per share exercise price of such Vested Stock Option. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.86 | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-17 · Disposition to issuer · Disposed 168,465 · Balance 0 F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option that was or became vested in accordance with its terms at the Effective Time (each, a "Vested Stock Option") was canceled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of Common Stock subject to such Vested Stock Option immediately prior to the Effective Time and (ii) the excess, if any, of (a) the Merger Consideration over (b) the per share exercise price of such Vested Stock Option. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.99 | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-17 · Disposition to issuer · Disposed 120,403 · Balance 0 F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option that was or became vested in accordance with its terms at the Effective Time (each, a "Vested Stock Option") was canceled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of Common Stock subject to such Vested Stock Option immediately prior to the Effective Time and (ii) the excess, if any, of (a) the Merger Consideration over (b) the per share exercise price of such Vested Stock Option. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.86 | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-17 · Disposition to issuer · Disposed 237,500 · Balance 0 F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option outstanding and unexercised immediately prior to the Effective Time that is not a Vested Stock Option was assumed by Parent and converted into an option to purchase Parent Class B Shares (each, an "Assumed Option"), with (i) the number of Parent Class B Shares subject to such Assumed Option equal to the product of (a) the number of shares of Common Stock that were issuable upon exercise of the Issuer stock option immediately prior to the Effective Time multiplied by (b) the Exchange Ratio and (ii) a per share exercise price equal to (a) the per share exercise price of the corresponding Issuer stock option divided by (b) the Exchange Ratio. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.86 | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-17 · Disposition to issuer · Disposed 370,623 · Balance 0 F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option outstanding and unexercised immediately prior to the Effective Time that is not a Vested Stock Option was assumed by Parent and converted into an option to purchase Parent Class B Shares (each, an "Assumed Option"), with (i) the number of Parent Class B Shares subject to such Assumed Option equal to the product of (a) the number of shares of Common Stock that were issuable upon exercise of the Issuer stock option immediately prior to the Effective Time multiplied by (b) the Exchange Ratio and (ii) a per share exercise price equal to (a) the per share exercise price of the corresponding Issuer stock option divided by (b) the Exchange Ratio. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.99 | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-17 · Disposition to issuer · Disposed 93,648 · Balance 0 F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option outstanding and unexercised immediately prior to the Effective Time that is not a Vested Stock Option was assumed by Parent and converted into an option to purchase Parent Class B Shares (each, an "Assumed Option"), with (i) the number of Parent Class B Shares subject to such Assumed Option equal to the product of (a) the number of shares of Common Stock that were issuable upon exercise of the Issuer stock option immediately prior to the Effective Time multiplied by (b) the Exchange Ratio and (ii) a per share exercise price equal to (a) the per share exercise price of the corresponding Issuer stock option divided by (b) the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time").
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding share of Issuer common stock, par value $0.0001 per share ("Common Stock") (other than shares of Common Stock canceled pursuant to the Merger Agreement) was converted into the right to receive $5.25 in cash (the "Merger Consideration").
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer restricted stock unit (an "RSU") outstanding immediately prior to the Effective Time that remains unvested at the Effective Time was assumed by Parent and converted into a Parent restricted stock unit award relating to a number of shares of Class B Common Stock, par value $0.01 per share, of Parent ("Parent Class B Shares") equal to the product of (i) the number of shares of Common Stock underlying such RSU, multiplied by (ii) a fraction (a) the numerator of which was the closing price of Common Stock on Nasdaq on the last day on which Common Stock was traded on Nasdaq that is immediately prior to the date of the Effective Time and (b) the denominator of which was the closing price of a Parent Class B Share on the New York Stock Exchange on the last day on which Common Stock was traded on Nasdaq that is immediately prior to the date of the Effective Time (the "Exchange Ratio").
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option that was or became vested in accordance with its terms at the Effective Time (each, a "Vested Stock Option") was canceled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of Common Stock subject to such Vested Stock Option immediately prior to the Effective Time and (ii) the excess, if any, of (a) the Merger Consideration over (b) the per share exercise price of such Vested Stock Option.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option outstanding and unexercised immediately prior to the Effective Time that is not a Vested Stock Option was assumed by Parent and converted into an option to purchase Parent Class B Shares (each, an "Assumed Option"), with (i) the number of Parent Class B Shares subject to such Assumed Option equal to the product of (a) the number of shares of Common Stock that were issuable upon exercise of the Issuer stock option immediately prior to the Effective Time multiplied by (b) the Exchange Ratio and (ii) a per share exercise price equal to (a) the per share exercise price of the corresponding Issuer stock option divided by (b) the Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2018 Filed Mar 7, 2018 00:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 5,393 | $101.00 | $544,693.00 |
DisclosureSEC source: 0001022079-18-000086 · wf-form4_152038303505837.xml · nonDerivative · entry 2 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,498 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 00:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 10,949 | $101.00 | $1,105,849.00 |
DisclosureSEC source: 0001022079-18-000086 · wf-form4_152038303505837.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,891 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 23, 2015, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 556 | $101.43 | $56,395.08 |
DisclosureSEC source: 0001022079-18-000058 · wf-form4_151993988288847.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,942 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,212 | $101.43 | $122,933.16 |
DisclosureSEC source: 0001022079-18-000050 · wf-form4_151976721013992.xml · nonDerivative · entry 2 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,498 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 387 | $102.69 | $39,741.03 |
DisclosureSEC source: 0001022079-18-000050 · wf-form4_151976721013992.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,710 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 19, 2018 Filed Feb 22, 2018 00:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 27,589 | $0.00 Strike: $103.57 | $0.00 |
DisclosureSEC source: 0001022079-18-000024 · wf-form4_151925945955674.xml · derivative · entry 2 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,589 Underlying: Common Stock · 27,589 shares Expires 2028-02-19 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 19, 2018 Filed Feb 22, 2018 00:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 2,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-18-000024 · wf-form4_151925945955674.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,097 F1 · shares: Represents an award of restricted share units. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-17-000163 · wf-form4_150179222829209.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,683 Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 63,880 | $52.17 Strike: $52.17 | $3,332,300.20 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · derivative · entry 12 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,880 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. F8 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 13, 2014, the second on February 13, 2015 and the final on February 13, 2016. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 29,340 | $56.12 Strike: $56.12 | $1,646,560.80 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · derivative · entry 11 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,340 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. F7 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 25, 2013 the second on February 25, 2014 and the final on February 25, 2015. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 13,680 | $57.61 Strike: $57.61 | $788,036.40 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · derivative · entry 10 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,680 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. F6 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 27, 2012, the second February 27, 2013 and the final on February 27, 2014. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 2,559 | $108.13 | $276,714.91 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · nonDerivative · entry 9 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,183 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $108.12 to $108.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 61,321 | $107.53 | $6,593,785.81 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · nonDerivative · entry 8 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,742 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $107.12 to $108.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 1,158 | $108.14 | $125,222.65 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · nonDerivative · entry 7 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,063 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $108.12 to $108.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 28,182 | $107.53 | $3,030,325.91 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · nonDerivative · entry 6 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,221 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $107.12 to $108.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 336 | $108.15 | $36,338.06 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · nonDerivative · entry 5 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,403 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $108.14 to $108.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 13,344 | $107.52 | $1,434,746.88 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · nonDerivative · entry 4 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,739 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $107.12 to $108.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 63,880 | $52.17 | $3,332,300.20 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · nonDerivative · entry 3 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 29,340 | $56.12 | $1,646,560.80 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · nonDerivative · entry 2 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:28 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 13,680 | $57.61 | $788,036.40 |
DisclosureSEC source: 0001022079-17-000151 · wf-form4_149807686777487.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 16, 2017. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 22:01 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 6,402 | $98.12 | $628,164.24 |
DisclosureSEC source: 0001022079-17-000091 · wf-form4_148857849342881.xml · nonDerivative · entry 2 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,183 F2 · acquired: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 22:01 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 12,520 | $98.12 | $1,228,462.40 |
DisclosureSEC source: 0001022079-17-000091 · wf-form4_148857849342881.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,585 F1 · acquired: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 13, 2014, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:41 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 420 | $96.42 | $40,496.40 |
DisclosureSEC source: 0001022079-17-000080 · wf-form4_148849085305492.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,065 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:41 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 459 | $95.68 | $43,917.12 |
DisclosureSEC source: 0001022079-17-000064 · wf-form4_148831807975381.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,485 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:11 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 37,565 | $0.00 Strike: $95.80 | $0.00 |
DisclosureSEC source: 0001022079-17-000044 · wf-form4_148789145927300.xml · derivative · entry 2 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,565 Underlying: Common Stock · 37,565 shares Expires 2027-02-21 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:11 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 3,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-17-000044 · wf-form4_148789145927300.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP & Group Exec. Diag. Sol. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,944 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,274 | $93.85 | $119,564.90 |
DisclosureSEC source: 0001022079-17-000018 · wf-form4_148719441808397.xml · nonDerivative · entry 1 Cohen Jon R · CIK 0001477972 · SVP, Diagnostic Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,812 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.